Literature DB >> 24130069

Gene-silencing antisense oligomers inhibit acinetobacter growth in vitro and in vivo.

Bruce L Geller1, Kimberly Marshall-Batty, Frederick J Schnell, Mattie M McKnight, Patrick L Iversen, David E Greenberg.   

Abstract

BACKGROUND: Peptide-conjugated phosphorodiamidate morpholino oligomers (PPMOs) are synthetic DNA/RNA analogues that silence expression of specific genes. We studied whether PPMOs targeted to essential genes in Acinetobacter lwoffii and Acinetobacter baumannii are active in vitro and in vivo.
METHODS: PPMOs were evaluated in vitro using minimum inhibitory concentration (MIC) and viability assays, and in vivo using murine pulmonary infection models with intranasal PPMO treatment.
RESULTS: MICs of PPMOs ranged from 0.1 to 64 µM (approximately 0.6-38 µg/mL). The most effective PPMO tested was (RXR)4-AcpP, which is targeted to acpP. (RXR)4-AcpP reduced viability of A. lwoffii and A. baumannii by >10(3) colony-forming units/mL at 5-8 times MIC. Mice treated with ≥0.25 mg/kg of (RXR)4-AcpP survived longer and had less inflammation and bacterial lung burden than mice treated with a scrambled-sequence PPMO or phosphate-buffered saline. Treatment could be delayed after infection and still increase survival.
CONCLUSIONS: PPMOs targeted to essential genes of A. lwoffii and A. baumannii were bactericidal and had MICs in a clinically relevant range. (RXR)4-AcpP increased survival of mice infected with A. lwoffii or A. baumannii, even when initial treatment was delayed after infection. PPMOs could be a viable therapeutic approach in dealing with multidrug-resistant Acinetobacter species.

Entities:  

Keywords:  Acinetobacter; MIC; PPMO; antisense; baumannii; infection; lwoffii; mouse; phosphorodiamidate morpholino oligomer; respiratory infection

Mesh:

Substances:

Year:  2013        PMID: 24130069      PMCID: PMC3805245          DOI: 10.1093/infdis/jit460

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  22 in total

1.  Stability of cell-penetrating peptide-morpholino oligomer conjugates in human serum and in cells.

Authors:  Derek S Youngblood; Susie A Hatlevig; Jed N Hassinger; Patrick L Iversen; Hong M Moulton
Journal:  Bioconjug Chem       Date:  2007 Jan-Feb       Impact factor: 4.774

2.  Antisense phosphorodiamidate morpholino oligomer length and target position effects on gene-specific inhibition in Escherichia coli.

Authors:  Jesse Deere; Pat Iversen; Bruce L Geller
Journal:  Antimicrob Agents Chemother       Date:  2005-01       Impact factor: 5.191

Review 3.  Global challenge of multidrug-resistant Acinetobacter baumannii.

Authors:  Federico Perez; Andrea M Hujer; Kristine M Hujer; Brooke K Decker; Philip N Rather; Robert A Bonomo
Journal:  Antimicrob Agents Chemother       Date:  2007-07-23       Impact factor: 5.191

4.  Gene-specific effects of antisense phosphorodiamidate morpholino oligomer-peptide conjugates on Escherichia coli and Salmonella enterica serovar typhimurium in pure culture and in tissue culture.

Authors:  Lucas D Tilley; Orion S Hine; Jill A Kellogg; Jed N Hassinger; Dwight D Weller; Patrick L Iversen; Bruce L Geller
Journal:  Antimicrob Agents Chemother       Date:  2006-08       Impact factor: 5.191

5.  Analysis of antibiotic resistance genes in multidrug-resistant Acinetobacter sp. isolates from military and civilian patients treated at the Walter Reed Army Medical Center.

Authors:  Kristine M Hujer; Andrea M Hujer; Edward A Hulten; Saralee Bajaksouzian; Jennifer M Adams; Curtis J Donskey; David J Ecker; Christian Massire; Mark W Eshoo; Rangarajan Sampath; Jodi M Thomson; Philip N Rather; David W Craft; Joel T Fishbain; Allesa J Ewell; Michael R Jacobs; David L Paterson; Robert A Bonomo
Journal:  Antimicrob Agents Chemother       Date:  2006-09-25       Impact factor: 5.191

6.  Antisense peptide-phosphorodiamidate morpholino oligomer conjugate: dose-response in mice infected with Escherichia coli.

Authors:  Lucas D Tilley; Brett L Mellbye; Susan E Puckett; Patrick L Iversen; Bruce L Geller
Journal:  J Antimicrob Chemother       Date:  2006-10-31       Impact factor: 5.790

7.  Comparative genomics of multidrug resistance in Acinetobacter baumannii.

Authors:  Pierre-Edouard Fournier; David Vallenet; Valérie Barbe; Stéphane Audic; Hiroyuki Ogata; Laurent Poirel; Hervé Richet; Catherine Robert; Sophie Mangenot; Chantal Abergel; Patrice Nordmann; Jean Weissenbach; Didier Raoult; Jean-Michel Claverie
Journal:  PLoS Genet       Date:  2006-01-13       Impact factor: 5.917

8.  Construction of Escherichia coli K-12 in-frame, single-gene knockout mutants: the Keio collection.

Authors:  Tomoya Baba; Takeshi Ara; Miki Hasegawa; Yuki Takai; Yoshiko Okumura; Miki Baba; Kirill A Datsenko; Masaru Tomita; Barry L Wanner; Hirotada Mori
Journal:  Mol Syst Biol       Date:  2006-02-21       Impact factor: 11.429

9.  Cell-penetrating peptides as transporters for morpholino oligomers: effects of amino acid composition on intracellular delivery and cytotoxicity.

Authors:  Rebecca P Wu; Derek S Youngblood; Jed N Hassinger; Candace E Lovejoy; Michelle H Nelson; Patrick L Iversen; Hong M Moulton
Journal:  Nucleic Acids Res       Date:  2007-08-01       Impact factor: 16.971

10.  Catheter-related bacteremia and multidrug-resistant Acinetobacter lwoffii.

Authors:  Luciano Tega; Katia Raieta; Donatella Ottaviani; Gian Luigi Russo; Giovanni Blanco; Antonio Carraturo
Journal:  Emerg Infect Dis       Date:  2007-02       Impact factor: 6.883

View more
  20 in total

Review 1.  Fighting against evolution of antibiotic resistance by utilizing evolvable antimicrobial drugs.

Authors:  Mehmet Fatih Cansizoglu; Erdal Toprak
Journal:  Curr Genet       Date:  2017-05-11       Impact factor: 3.886

2.  Antimicrobial activity of antisense peptide-peptide nucleic acid conjugates against non-typeable Haemophilus influenzae in planktonic and biofilm forms.

Authors:  Taketo Otsuka; Aimee L Brauer; Charmaine Kirkham; Erin K Sully; Melinda M Pettigrew; Yong Kong; Bruce L Geller; Timothy F Murphy
Journal:  J Antimicrob Chemother       Date:  2016-09-28       Impact factor: 5.790

Review 3.  Advances in therapeutic bacterial antisense biotechnology.

Authors:  John P Hegarty; David B Stewart
Journal:  Appl Microbiol Biotechnol       Date:  2017-12-05       Impact factor: 4.813

Review 4.  Next-generation precision antimicrobials: towards personalized treatment of infectious diseases.

Authors:  Cesar de la Fuente-Nunez; Marcelo Dt Torres; Francisco Jm Mojica; Timothy K Lu
Journal:  Curr Opin Microbiol       Date:  2017-06-14       Impact factor: 7.934

5.  Inhibition of Bacterial Growth by Peptide-Conjugated Morpholino Oligomers.

Authors:  Seth M Daly; Carolyn R Sturge; David E Greenberg
Journal:  Methods Mol Biol       Date:  2017

6.  Inhibition of Pseudomonas aeruginosa by Peptide-Conjugated Phosphorodiamidate Morpholino Oligomers.

Authors:  James J Howard; Carolyn R Sturge; Dina A Moustafa; Seth M Daly; Kimberly R Marshall-Batty; Christina F Felder; Danniel Zamora; Marium Yabe-Gill; Maria Labandeira-Rey; Stacey M Bailey; Michael Wong; Joanna B Goldberg; Bruce L Geller; David E Greenberg
Journal:  Antimicrob Agents Chemother       Date:  2017-03-24       Impact factor: 5.191

7.  Morpholino oligomers tested in vitro, in biofilm and in vivo against multidrug-resistant Klebsiella pneumoniae.

Authors:  Bruce L Geller; Lixin Li; Fabian Martinez; Erin Sully; Carolyn R Sturge; Seth M Daly; Christine Pybus; David E Greenberg
Journal:  J Antimicrob Chemother       Date:  2018-06-01       Impact factor: 5.790

8.  Inhibition of AAC(6')-Ib-mediated resistance to amikacin in Acinetobacter baumannii by an antisense peptide-conjugated 2',4'-bridged nucleic acid-NC-DNA hybrid oligomer.

Authors:  Christina Lopez; Brock A Arivett; Luis A Actis; Marcelo E Tolmasky
Journal:  Antimicrob Agents Chemother       Date:  2015-07-13       Impact factor: 5.191

9.  Anti-Sense Antibiotic Agents as Treatment for Bacterial Infections.

Authors:  David B Stewart
Journal:  Surg Infect (Larchmt)       Date:  2018-09-25       Impact factor: 2.150

Review 10.  One cannot rule them all: Are bacterial toxins-antitoxins druggable?

Authors:  Wai Ting Chan; Dolors Balsa; Manuel Espinosa
Journal:  FEMS Microbiol Rev       Date:  2015-03-21       Impact factor: 16.408

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.